leadf
logo-loader
viewImugene Limited
(
ASX:IMUOTC:IUGNF
)

Imugene reveals encouraging HER-Vaxx gastric cancer data, plans three new trials

HER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

Imugene Limited - Imugene reveals encouraging HER-Vaxx gastric cancer data, plans three new trials

Imugene Limited (ASX:IMU, OTC:IUGNF), a clinical-stage immune-oncology company, has revealed secondary efficacy endpoint progression-free survival (PFS) data for its HER-Vaxx immunotherapy in HER-2 positive gastric cancer.

The Phase 2 HER-Vaxx clinical trial is designed to evaluate the efficacy, safety and immune response in metastatic gastric cancer overexpressing the HER-2 protein.

Based on these results, Imugene now plans two further company-sponsored phase 2 studies and one investigator-sponsored study with HER-Vaxx in early and late-stage gastric cancer.

“Encouraged by PFS”

Imugene MD and CEO Leslie Chong said: “We are encouraged by the PFS and anticipated primary OS clinical data to commence three new HER-Vaxx trials, to be called NextHERIZON, NeoHERIZON and NeuHERIZON, in early and late-stage gastric cancer including combination with PD-1 and PD-L1 checkpoint inhibitors.

“These studies will be conducted in the US, Australia and South Korea.”

The study

The study is randomised into two arms of either HER-Vaxx plus standard-of-care (SOC) chemotherapy or SOC chemotherapy alone.

Primary endpoint is overall survival (OS) and the secondary endpoint includes PFS by independent central review.

To date, 36 patients have been enrolled and 24 have achieved a PFS event in this signal generating study.

Imugene is awaiting the events needed for OS evaluation and will subsequently analyse all data including final OS, PFS, safety, and immune responses.

Ongoing studies

Imugene’s HER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu.

It has been shown in pre-clinical studies, in phase I and now phase 2 studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

The HERIZON Phase 2 trial, which has completed recruitment, is being conducted at multiple sites across Eastern Europe and India where clinicians have difficulty accessing approved antibody treatments such as Herceptin®.

- Ephrems Joseph

Quick facts: Imugene Limited

Follow
ASX:IMU

Price: 0.48 AUD

Market Cap: $2.62 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene's Leslie Chong outlines key strategic partnership with Celularity

Imugene Ltd's Leslie Chong speaks to Proactive's Andrew Scott soon after announcing they've entered into a research collaboration with Celularity Inc to develop a novel oncolytic virus allogeneic CAR T-Cell immunotherapy combination for the treatment of solid tumors. As part of the partnership...

on 9/8/21

2 min read